Zavegepant
Names | |
---|---|
Trade names | Zavzpret |
Other names | BHV-3500 |
IUPAC name
| |
Clinical data | |
Drug class | Calcitonin gene-related peptide receptor antagonist[1] |
Main uses | Migraine headaches[1] |
Side effects | Taste changes, nausea, sore nose, vomiting[1] |
WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
Routes of use | Nasal |
Typical dose | 10 mg[1] |
External links | |
AHFS/Drugs.com | Monograph |
Legal | |
License data |
|
Legal status | |
Chemical and physical data | |
Formula | C36H46N8O3 |
Molar mass | 638.817 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Zavegepant, sold under the brand name Zavzpret, is a medication used to treat migraine headaches.[1] It is used for the headache itself, rather than prevention.[1] It is sprayed into the nose.[1]
Common side effects include taste changes, nausea, sore nose, and vomiting.[1] Other side effects include allergic reactions.[1] Use is not recommended in people with significant liver or kidney problems.[1] Safety in pregnancy is unclear.[1] It is a calcitonin gene-related peptide receptor antagonist.[1]
Zavegepant was approved for medical use in the United States in 2023.[1] It is expected to become commercially available in July of 2023 and be priced similar to other medications in its class.[2]
Medical uses
Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.[1]
Dosage
It is given at a dose of 10 mg, with at most one dose per day.[1]
Society and culture
It is sold by Pfizer.[1]
References
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 "ZAVZPRET™ (zavegepant) nasal spray" (PDF). Archived (PDF) from the original on 2023-03-11. Retrieved 2023-03-13.
- ↑ MSc, Nadia Stec (14 March 2023). "Zavzpret (Zavegepant) Migraine Nasal Spray from Pfizer Gets FDA Nod". Xtalks. Archived from the original on 15 March 2023. Retrieved 25 May 2023.
External links
Identifiers: |
---|
- Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, et al. (2022). "A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine". Health Psychology Research. 10 (3): 35506. doi:10.52965/001c.35506. PMC 9239361. PMID 35774914.
- Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT (November 2022). "Focus on zavegepant: the first intranasal third-generation gepant". Pain Management. 12 (8): 879–885. doi:10.2217/pmt-2022-0054. PMID 36189708. S2CID 252681912.
- Clinical trial number NCT04571060 for "Randomized Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov
- Clinical trial number NCT03872453 for "Acute Treatment Trial in Adult Subjects With Migraines" at ClinicalTrials.gov